Brokers Offer Predictions for SPRY FY2029 Earnings

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Research analysts at Leerink Partnrs issued their FY2029 earnings estimates for shares of ARS Pharmaceuticals in a note issued to investors on Sunday, June 22nd. Leerink Partnrs analyst R. Ruiz anticipates that the company will post earnings of $3.55 per share for the year. The consensus estimate for ARS Pharmaceuticals' current full-year earnings is ($0.55) per share.

Several other research firms have also recently issued reports on SPRY. Scotiabank started coverage on shares of ARS Pharmaceuticals in a research report on Friday, March 7th. They set a "sector outperform" rating and a $30.00 price objective for the company. William Blair reissued an "outperform" rating on shares of ARS Pharmaceuticals in a research report on Monday, March 3rd. Finally, Wall Street Zen cut shares of ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, ARS Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $31.00.

ARS Pharmaceuticals Price Performance

ARS Pharmaceuticals stock opened at $16.57 on Tuesday. The stock has a market cap of $1.63 billion, a P/E ratio of -103.56 and a beta of 0.84. The company has a fifty day simple moving average of $14.42 and a 200-day simple moving average of $12.90. ARS Pharmaceuticals has a 12-month low of $7.55 and a 12-month high of $18.51. The company has a current ratio of 11.00, a quick ratio of 10.74 and a debt-to-equity ratio of 0.30.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.35). The business had revenue of $7.97 million during the quarter, compared to analysts' expectations of $7.48 million. ARS Pharmaceuticals had a negative net margin of 16.11% and a negative return on equity of 6.94%.

Institutional Investors Weigh In On ARS Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Bernard Wealth Management Corp. acquired a new position in shares of ARS Pharmaceuticals during the fourth quarter worth about $27,000. ANTIPODES PARTNERS Ltd acquired a new position in shares of ARS Pharmaceuticals during the first quarter worth about $37,000. GAMMA Investing LLC increased its stake in shares of ARS Pharmaceuticals by 4,319.7% during the first quarter. GAMMA Investing LLC now owns 3,359 shares of the company's stock worth $420,000 after acquiring an additional 3,283 shares during the period. PNC Financial Services Group Inc. increased its stake in shares of ARS Pharmaceuticals by 78,100.0% during the first quarter. PNC Financial Services Group Inc. now owns 3,910 shares of the company's stock worth $49,000 after acquiring an additional 3,905 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of ARS Pharmaceuticals during the fourth quarter worth about $73,000. 68.16% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at ARS Pharmaceuticals

In other news, insider Alexander A. Fitzpatrick sold 102,969 shares of the company's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $14.10, for a total value of $1,451,862.90. Following the completion of the sale, the insider now directly owns 89,613 shares of the company's stock, valued at approximately $1,263,543.30. This represents a 53.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eric Karas sold 15,000 shares of the company's stock in a transaction dated Wednesday, June 18th. The shares were sold at an average price of $16.00, for a total transaction of $240,000.00. Following the completion of the sale, the insider now directly owns 7,696 shares of the company's stock, valued at $123,136. The trade was a 66.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 337,971 shares of company stock valued at $4,721,888 over the last ninety days. Insiders own 33.50% of the company's stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.